Independent
Tenure on this board
7.6 yrs
Also a director at
Alterity Therapeutics Ltd (ATHE)
4 nominees · 3 ballot items.
Stockholders will vote to elect four directors, to cast a non-binding advisory vote to approve executive compensation (Say-on-Pay), and to ratify KPMG LLP as the company's independent registered public accounting firm for fiscal 2027.
Elect four continuing director nominees (Ann M. Cunningham, Jon S. Saxe, Shawn K. Singh and Douglas J. Williamson) to the Board, each to serve until the next annual meeting or until a successor is elected and qualified.
Non-binding, advisory vote to approve the compensation paid to the Company's Named Executive Officers as disclosed in the proxy statement (Say-on-Pay).
This non-binding advisory proposal asks stockholders to approve the Company’s disclosed executive compensation for Named Executive Officers (NEOs). Management is seeking this advisory endorsement to validate its compensation philosophy and practices—designed to attract, retain and motivate executives through a mix of base salary, discretionary cash bonuses, and equity incentives—and to demonstrate alignment with stockholder interests. The proposal is explicitly non-binding, but the Board and Compensation Committee state they will consider the vote outcome when setting future pay decisions, making the vote an important signal of shareholder sentiment. Contextually, the Company recently experienced a clinical setback (PALISADE-3 trial did not meet endpoints), which led the Board to forego performance-based compensation for Fiscal 2026 while approving limited retention bonuses for certain executives; this background may influence investor views on pay-for-performance alignment. The filing discloses pay components, recent retention inducements and long-term equity grants, and provides pay-versus-performance tables required by SEC rules—information shareholders will weigh when deciding whether to support management’s approach. Management argues the compensation program is market-competitive, aligned with corporate goals and includes significant equity-based incentives to tie executives’ interests to long-term value creation. Opposition risks include perceptions that compensation was awarded despite trial failures or that retention bonuses and certain inducement awards are insufficiently performance-based; however, management highlights prior strong shareholder support (over 97% in 2025) as evidence of alignment. Given the advisory nature, a negative vote would not overturn pay actions but would likely prompt the Compensation Committee and Board to engage with investors and potentially adjust program design or disclosures. The Board’s recommendation to vote FOR is based on its view that the pay program supports strategic objectives and talent retention while being responsive to shareholder feedback through ongoing engagement.
Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2027.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Commodore Capital LP | 6.28% | 2,788,620 | $630K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.55% | 1,574,200 | $356K |
| 3 | TWO SIGMA INVESTMENTS, LP | 1.91% | 847,992 | $192K |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 1.79% | 794,579 | $178 |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 1.65% | 730,500 | $165K |
| 6 | STEMPOINT CAPITAL LP | 1.39% | 616,749 | $17K |
| 7 | Ikarian Capital, LLC | 1.17% | 519,077 | $117K |
| 8 | AdvisorShares Investments LLC | 0.99% | 438,643 | $99K |
| 9 | LUMINUS MANAGEMENT LLC | 0.91% | 403,115 | $91K |
| 10 | ADAR1 Capital Management, LLC | 0.79% | 351,141 | $79K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.